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Background: Silent brain infarcts are detected by neuroimaging in up to 20% of asymptomatic patients based on
population studies. They are five times more frequent than stroke in general population, and increase significantly
both with advancing age and hypertension. Moreover, they are independently associated with the risk of future
stroke and cognitive decline.
Despite these numbers and the clinical consequences of silent brain infarcts, their prevalence in Mediterranean
populations is not well known and their role as predictors of future cerebrovascular and cardiovascular events in
hypertensive remains to be determined.
ISSYS (Investigating Silent Strokes in Hypertensives: a magnetic resonance imaging study) is an observational cross-
sectional and longitudinal study aimed to: 1- determine the prevalence of silent cerebrovascular infarcts in a large
cohort of 1000 hypertensives and to study their associated factors and 2-to study their relationship with the risk of
future stroke and cognitive decline.
Methods/Design: Cohort study in a randomly selected sample of 1000 participants, hypertensive aged 50 to
70 years old, with no history of previous stroke or dementia.
On baseline all participants will undergo a brain MRI to determine the presence of brain infarcts and other
cerebrovascular lesions (brain microbleeds, white matter changes and enlarged perivascular spaces) and will be also
tested to determine other than brain organ damage (heart-left ventricular hypertrophy, kidney-urine albumin to
creatinine ratio, vessels-pulse wave velocity, ankle brachial index), in order to establish the contribution of other
subclinical conditions to the risk of further vascular events. Several sub-studies assessing the role of 24 hour
ambulatory BP monitoring and plasma or genetic biomarkers will be performed.
Follow-up will last for at least 3 years, to assess the rate of further stroke/transient ischemic attack, other
cardiovascular events and cognitive decline, and their predictors.
Discussion: Improving the knowledge on the frequency and determinants of these lesions in our setting might
help in the future to optimize treatments or establish new preventive strategies to minimize clinical and
socioeconomic consequences of stroke and cognitive decline.* Correspondence: pilar.delgado@vhir.org
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Hypertension is the most important modifiable vascular
risk factor for stroke and it is commonly widespread in
the aging population.
For a long time, treatment for hypertension has been
focused on blood pressure (BP) levels as the main mea-
sure to determine the need and type of treatment. This
approach has changed over the past years, emphasizing
that diagnosis and treatment should be based on the
quantification of global cardiovascular risk. According to
the European guidelines on hypertension [1], common
variables used to stratify risk are based on the presence
of vascular risk factors (family history of premature car-
diovascular disease, smoking habits, glucose and lipid
parameters) plus further identification of clinical or sub-
clinical target organ damage. Hypertension-related dis-
ease in several organs might indicate progression and
markedly increase the risk beyond that caused by the BP
levels or risk factors presence.
Since evidences advise for different goals of treatment
in high risk individuals as compared with lower risk hy-
pertensives [1], whenever possible, it is recommended to
measure target organ damage in different tissues (i.e.
heart, blood vessels, kidney and brain) because multiorgan
damage is associated with worse prognosis [2]. Many
different markers have been already described, such as
electrocardiographic/echocardiographic markers, intima
media thickness, pulse wave velocity as a marker of arter-
ial stiffness or markers of endothelial dysfunction, among
others, that can be useful identifying target organ damage.
The main limitations are of course, costs and availability
of diagnostic procedures and particularly for subclinical
conditions, there is still limited knowledge on their pre-
dictive capacity for risk evaluation.
Regarding brain as hypertension target organ, subclin-
ical or “silent” vascular brain lesions (i.e. infarcts, micro-
bleeds, white matter changes) are often detected by
neuroimaging in asymptomatic patients. Specifically,
silent brain infarcts are five times more frequent than
stroke in general population, and increase significantly
both with advancing age and hypertension [3]. The term
“silent” might not be entirely appropriate since these
lesions could be often associated with unnoticed or sub-
tle symptoms in patients that never asked for an evalu-
ation, making impossible a diagnosis of stroke. The
prognosis associated with these “silent” infarcts is not
favourable at all, and their presence independently pre-
dicts further stroke and cognitive decline [4,5]. For all
these reasons, silent brain infarcts have been recently
included in the AHA Updated definition of stroke, thus
emphasizing their clinical relevance [6]. This will have
important consequences in public health, as it is
expected to largely increase stroke prevalence. Moreover,
their detection might have the potential to improve theselection of patients at higher risk for future stroke and
cardiovascular events, who might benefit from more
aggressive preventive treatments.
Hypertension has been related not only to the pres-
ence of silent vascular brain lesions but to the appear-
ance of new lesions on follow-up, which can occur in up
to 40%, considering progression of white matter changes
[7]. Interestingly, this effect on progression is much
more relevant at younger or midlife patients than later
on [7,8]. Therefore, preventive strategies should pay
much more attention to younger subjects, who are likely
to have long term exposure to an increased risk in the
following years [1].
Studies focusing on hypertensive participants have been
performed, and reported a prevalence of silent brain
infarcts that ranges from 20 to 86% of subjects aged 40 to
88 years old. Of note, most of these studies have included
mainly Japanese populations, whereas data on Mediterranean
Caucasian populations is still limited [7].
With this background, the ISSYS is designed as a
cross-sectional and longitudinal study aimed to: (1) in-
vestigate the prevalence of silent cerebrovascular lesions,
as signatures of brain organ damage, in a cohort of mid-
dle and advanced aged (50–70 years old) caucasian
Mediterranian hypertensives and (2) to study their rela-
tionship with the risk of future stroke and cognitive
decline.
Methods/Design
ISSYS (Investigating Silent Strokes in Hypertensives: a
magnetic resonance imaging study) is an observational
cross-sectional and longitudinal study aimed to deter-
mine the prevalence of silent cerebrovascular lesions in
a large cohort of hypertensives and to study their associ-
ated factors.
On baseline all participants will be also tested to deter-
mine other than brain (vascular, kidney, heart) organ
damage, in order to establish the contribution of other
subclinical conditions to global vascular risk.
Follow-up is planned to last for at least 3 years, to assess
the rate of further Stroke/TIA and cardiovascular events
as well as cognitive impairment, and their predictors.
Subject selection
The basic design of ISSYS is a cohort study among
87000 persons aged 50 to 70 years old and living in the
district of the north metropolitan area of Barcelona
(SAP Muntanya). This site was chosen for several rea-
sons. First, in the Primary Healthcare system there is a
computer-based registry for all patients in this area who
mainly attend these services rather than other private
options. Second, the study is coordinated between the
Primary HealthCare services in this area and the re-
searchers from Research Institute and Vall d’Hebron
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The study is carried out in patients diagnosed of es-
sential hypertension who are routinely attended by gen-
eral practitioners. According to the registry, around
27000 participants could be eligible for the study, since
they are hypertensives and stroke-free and have been
randomized after stratification by age, gender and preva-
lence of hypertension covering all the area.
After randomization, patients have been invited by
phone to participate in the study and scheduled for a
baseline evaluation at their own Primary Care centre.
Estimated sample size will be 1000 participants, who
will be enrolled during 18 months and then participants
will be followed-up, for at least three years.
The study protocol has been approved by the Ethics
Committee of Vall d’Hebron Hospital and IDIAP Jordi
Gol (University Research Institute in Primary Care).
Baseline visit and procedures
Inclusion and exclusion criteria
At inclusion visit, fulfilment of inclusion and exclusion
criteria is re-assessed by investigators. Briefly, inclusion
criteria consists on: 1)Patients with essential hyperten-
sion diagnosed at least one year earlier; 2) Age com-
prised between 50 and 70 years; 3) Patients who give
their consent to participate in the study.
Patients are excluded when: 1) they have history of
previous stroke or dementia; 2) Brain MRI is contraindi-
cated; 3) there is a suspicion of white coat hypertension
syndrome or 4) patients affected by a terminal illnessFigure 1 ISSYS procedures and outcomes for baseline and follow-uppreventing future follow-up examinations, based on the
investigator criteria.
A particular effort is made to rule out the presence of
a previous stroke, and for that purpose investigators are
trained and an adaptation of the Stroke Symptom Ques-
tionnaire by Berger K and collaborators is used [9].
Likewise, when a suspicion of dementia appears, fol-
lowing DSM-IV-R criteria [10] the patient is not in-
cluded in the study and a proper evaluation in the
presence of a caregiver is therefore recommended.
Clinical data collection
All procedures for baseline and follow-up visits are sum-
marized in Figure 1.
After inclusion, the participant is asked about demo-
graphical and personal medical history. Briefly, demo-
graphical information includes age, gender, ethnicity,
current or former occupation, and the maximum educa-
tional level (or completed years of schooling) achieved
by the patient.
Regarding medical history, the participant is asked
about the duration of hypertension, the presence of
other vascular risk factors such as diabetes mellitus,
hyperlipidemia, alcohol intake (grams per week), smok-
ing habit (current, former, never) and family history of
premature vascular disease and dementia in first grade
relatives.
Also a directed questioning is performed to assess for
the existence of an established cardiovascular, kidney or
systemic disease, together with the history of retinal ab-
normalities or the presence of a sleep apnea syndrome.visits.
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risk charts and Framingham-calibrated REGICOR func-
tion when appropriate [11,12].
Data concerning ambulatory and home blood pressure,
home medication and treatment adherence is collected.
To evaluate treatment adherence, the validated question-
naire published by Morisky and collaborators [13] is
used. Briefly, this scale was developed to assess treat-
ment compliance in hypertension and currently is used
in many other chronic conditions. It consists in 4 ques-
tions, with yes/no answers which should be asked along
the clinical interview, and reflect the patient’s attitude
towards treatment. It is useful to find out whether or
not the patient is a good complier and the causes for
non-adherence.
Finally, the clinical interview ends with two self-
administered questionnaires assessing life-style habits
(physical activity and diet). Physical activity is evaluated by
means of the International Physical Activity Questionnaire
(IPAQ) [14] and dietetic habits are evaluated with a short
questionnaire on frequency of dietary intake [15].
Physical examination and vascular testing
Regarding physical examination, some measures are
taken and recorded such as height, weight, waist circum-
ference and BP (mean of the last two out of three mea-
surements after five minutes rest).
Plus, a standard 12-lead ECG is performed to assess
for signs of left ventricular hypertrophy (single measure-
ment of R wave in aVL [16]) and heart rhythm disorders.
Afterwards, vascular testing is performed with the
Vicorder™ device (Skidmore Medical Ltd, Bristol, UK).
The Vicorder™ is small, portable, non-invasive and non-
operator dependent device suited for use in community
based studies [17]. This system provides two BP meas-
urement channels and two Photoplethysmography (PPG)
channels for the measurement of blood flow.
Briefly, two measurements are taken for each patient:
carotid-femoral pulse wave velocity (cf-PWV) and the
ankle-brachial index (ABI).
Cf-PWV is measured as the best approximation of aor-
tic pulse wave velocity (aPWV), a marker of arterial stiff-
ness. For the measurement, the patient should be resting
in a supine position, with the head and shoulders raised
by about 30 degrees allowing venous return from the
brain and avoiding signal contamination by the Jugular
vein. A neck-pad should be placed at the lower centre
part of the Right Common Carotid Artery as tightened
as possible without discomforting the patient. A distal
BP cuff should be located on the ipsilateral upper thigh,
as high to the groin as possible. The neck-pad and thigh
cuff are inflated by the Vicorder to 60 mmHg and then
deflated to obtain a pressure tracing. Cf-PWV is calcu-
lated by the Vicorder by comparing carotid and femoralpressure tracings after a stable pattern is obtained. Then,
cf-PWV is defined as the ratio of the distance between
the carotid and the thigh position and the time it takes
for the pulse wave to travel from the proximal to the
distal locations. For anatomical reasons, the distance
between suprasternal notch and the centre of femoral
cuff is chosen as the best estimation of the distance
between the two arterial sites.
ABI is measured according to the current guidelines of
the American Heart Association for each side as the
ratio of the highest systolic BP of each ankle and the
highest systolic BP of both upper limbs [18]. The lowest
of the right and left ABI values will be used.
In this case, systolic BP is determined by PPG, and as
it has been previously described [19]. PPG is a fast and
accurate technique and can be considered a good alter-
native to Doppler ABI measurement. Both sides can be
examined simultaneously. Briefly, a cuff is placed around
the limb of interest and a PPG signal is obtained distal
to the cuff. Then, the cuff is inflated to a pre-defined
target pressure and afterwards the cuff will automatically
bleed pressure and the PPG signal reappears when the
systolic BP is reached.
Cognitive assessment
On baseline, all patients will be evaluated by means of
the Dementia Rating Scale-2 developed by Mattis, which
is a screening tool for dementia and mild cognitive
impairment. Our complete cognitive assessment proto-
col on baseline and follow-up has been published in
detail previously [20].
Laboratory testing
A blood sample will be drawn after overnight fast where
the basic hematology (hemoglobine, leukocyte and platelet
count) and biochemistry profile (glucose, total cholesterol,
creatinine, sodium, potassium and liver function) are de-
termined. Also, plasma and serum will be obtained on
baseline visit after 15 minutes centrifugation (3500 rpm)
and frozen at −80°C for future biomarker determination.
DNA and RNA will be also obtained and stored for further
studies.
Finally, a urine sample will be collected and sent to
central laboratory for albumin to creatinine ratio (UACR)
determination.
Neuroimaging protocol
A brain MRI with a pre-stablish data acquisition proto-
col (Table 1) will be performed within the next month
after study entry. All examinations will be performed
with the same 1.5 Tesla MR (Signa HDx 1.5, General
Electrics, Waukeska, WI). MR will include axial and
sagittal T1 weighted images. Midline sagittal images will
be used to identify the anterior-posterior commissure
Table 1 MRI parameters in the ISSYS
Sequence Mode Time TR/TE TI Number
of slices
Slice thickness/gap (mm) FOV Matrix
Localizer 3D
SE SAG T1-w 2D 3:06 400/10 20 5/1.5 256 256x224
SE AX T1-w 2D 2:58 520/10 24 5/1.0 256 256x224
Propeller AX T2-w 2D 2:40 5500/125 20 5/1.5 256 448
AX FLAIR 2D 3:20 10000/120 2200 20 5/1.5 256 320x192
AX GRE 2D 1:55 675/18 20 5/1.5 256 288x224
SE Spin Echo, SAG Sagital, AX Axial, Propeller Periodically Rotated Overlapping Parallel Lines with Enhanced Reconstruction, FLAIR Fluid Liquid Attenuated Inversion
Recovery, GRE Gradient Echo, TR Repetition Time, TE Echo Time, FOV field of view, Matrix (Frequency x Phase).
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Also, Axial Propeller T2-weighted images, axial fluid-
attenuated inversion recovery (FLAIR) and axial GRE
images will be obtained. Images will be displayed on
workstations monitors to be evaluated by trained readers
blinded to patients’ characteristics. All images will be
primarily assessed by two neuroradiologists and in a sec-
ond term by the same readers plus an experienced
stroke neurologist. Intra and inter-reader concordance
will be provided for all lesions of interest and disagree-
ments in assessment will be solved by consensus.
Silent brain infarcts will be defined as previously [21]
as lesions of ≥ 3 mm in diameter in their widest dimen-
sion, with cerebrospinal fluid signal characteristics in all
pulse sequences, and with a hyperintense rim surround-
ing the lesion in FLAIR images. A particular effort will
be made to differentiate these cavitated lacunes from
large dilated perivascular spaces for lesions >3 mm,
based on location criteria. Lesions located in areas with
high prevalence of enlarged perivascular spaces, such as
the lower third of basal ganglia will not be considered as
infarcts. Anatomical localization for infarcts will be
recorded as cortical, subcortical, basal ganglia, brainstem
and cerebellum and number of lesions will be counted
in case of multiple lesions.
An additional analysis will be performed for lacunar
infarcts, defined as those of minimum 3 mm diameter
and maximum 20 mm, located at the basal ganglia, in-
ternal capsules, thalamus, deep cerebral white matter
and brainstem. An infarct located in the cortex, even if
it reaches the subcortex will be recorded as cortical.
White matter hyperintensities will be rated according
to the Age-related white matter changes (ARWMC)
scale developed by Wahlund and col [22] that assesses
presence and severity of white matter changes in the
frontal, parietooccipital, temporal, basal ganglia and
infratentorial areas separately in each hemisphere, ran-
ging from 0 to 30 points.
Enlarged perivascular spaces (EPVs) or Virchow-Robin
spaces will be defined as small (<3 mm), sharply delin-
eated structures of cerebrospinal fluid (CSF) intensityfollowing the course of perforating vessels and will be
rated in T2-weighted images at the centrum semiovale,
basal ganglia and midbrain following the scale reported
by Doubal and collaborators [23]. Briefly, for basal gan-
glia and centrum semiovale, the rating will be as follows:
0: Absent; 1: Mild (from 1 to 10 EPVs); 2: Moderate
(from 11 to 20 EPVs); 3: Frequent (from 21 to 40 EPVs);
4: Severe (more than 40 EPVs). For midbrain a rating of
0 will be considered when no EPVs is visible, and a rat-
ing of 1 when they are visible. For rating purposes, both
hemispheres will be considered separately and the
highest score of them will be chosen.
The presence of brain microbleeds, together with their
number and location will be recorded following the
Brain Observer Microbleed Scale (BOMBS) scale devel-
oped by Cordonnier and collaborators [24].
Representative MRI images for the lesions of interest
are shown at Figure 2.
Follow-up visits
The participants will be contacted yearly by phone, one
and two years after the inclusion visit. They will be asked
about BP control, appearance of new vascular risk factors,
and the presence of stroke/TIA or new vascular events. In
case of any event has occurred, this will be verified by
checking clinical records from their family doctors and
hospital records. Participants will also be asked about
medical treatment adherence using the same question-
naire performed at baseline and treatment adverse events.
Finally, three years after inclusion a new visit is
planned by the investigator’s team at the primary care
center where the patient belongs, when data relative to
new medical history and physical examination (blood
pressure, height and weight and waist circumference
measurement) will be collected, together with a new
cognitive assessment with the Dementia Rating Scale-2.
Preventive treatments during follow-up
After baseline visit is completed and MRI is performed,
primary care physicians will receive a summary with the
most relevant results for each participant. Family doctors
Figure 2 Representative examples of subclinical/silent cerebrovascular lesions. From left to right: Brain infarct affecting caudate nuclei
(FLAIR MRI), brain microbleed in left thalamus (GRE MRI), enlarged perivascular spaces involving basal ganglia (T2 MRI) and extensive white matter
changes (FLAIR MRI).
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their routine practice. As for silent brain infarcts, since at
present there is no clear evidence of whether a secondary
stroke prevention should be applied to these patients and
until new information comes from randomized clinical
trials, recommendations will be to optimize BP control in
all cases as much as possible and considering start
antiplatelet treatment and/or cholesterol-lowering drugs
in cases with the estimated global vascular risk is high
(≥10 score in the Framingham-calibrated REGICOR
function) [1].
Study outcome
The primary outcomes of this study are the determin-
ation of the prevalence of silent brain infarctions and
other silent lesions (as described in the neuroimaging
protocol) and the presence and time to first-ever stroke
(fatal or non-fatal ischemic or hemorrhagic stroke) or
TIA. Stroke will be defined clinically as a focal neuro-
logical deficit thought of vascular origin, lasting more than
24 hours and confirmed by clinical evaluation and the use
of a brain CT scan or MRI. TIA will be defined according
to the classical definition, as an acute focal neurologic
deficit due to cerebral ischemia that resolves completely
within 24 hours, regardless of neuroimaging findings.
Other cardiovascular events will be analysed as sec-
ondary events: coronary events (myocardial infarction,
angina requiring hospitalization, coronary angioplasty or
surgery); cardiac failure requiring admission to hospital;
vascular complications (lower limbs, aorta or carotid
arteries) requiring revascularization and vascular death.
Finally, cognitive decline will be evaluated as second-
ary end-point during follow-up.
Substudies (case–control studies nested in the ISSYS cohort)
Twenty-four hour ambulatory blood pressure monitoring
(ABPM)
A nested case–control study within the ISSYS cohort will
be performed with 24-hour ambulatory BP monitoring.Cases will be considered as participants in whom silent
brain infarctions are detected versus controls (participants
with no brain infarctions). Cases will be matched with
controls by age, gender, other vascular risk factors and
antihypertensive treatment in a ratio of 1 to 2/ 1 to 3.
Oscillometric ABPM measurements will be obtained
using a Spacelabs 90217-5Q device (Spacelabs Healthcare,
Issaquah, Washington, USA), validated according to the
protocol of the British Hypertension Society [25]. The BP
measurements will be made every 20 minutes during day-
time and every 30 minutes during sleeptime in a day of
standard activity and with a cuff suited to the size of the
patient’s arm. All recordings with at least 70% of valid
readings or at least 45 measurements will be considered
for the analysis.
Daytime ambulatory hypertension will be defined as a
mean daytime BP ≥ 135/85 mmHg and sleeptime ambu-
latory hypertension as a mean BP ≥ 120/70 mmHg,
according to the ESH Guidelines(1).
Circadian BP patterns will be assessed, considering a
nondipping status as a night to day ratio of mean sys-
tolic blood pressure (SBP) of 0.9 or more. Also the
sleep-through morning surge defined as the morning BP
(2-hour average of four 30-minute BP readings just after
wake-up) minus the lowest nocturnal BP (1-hour aver-
age of the 3 BP readings centered on the lowest night-
time reading) will be calculated [26].
Biomarkers determination
Also, substudies on protein and genetic biomarkers will
be performed following the same strategy of a case–
control study nested in this cohort.
Follow-up neuroimaging studies
A follow-up MRI is planned after the third year of
follow-up for a nested cohort of cases and controls
according to the presence of silent infarcts at baseline.
This will allow us to describe the incidence of new
lesions.
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Data will be collected by investigators and supporting
staff and transferred to an electronic case report form
(eCRF) on a weekly basis. No personal data enabling the
identification of the participants will be included in the
eCRF. Previous training is warranted for all investigators
before access to the live database. Data are secured from
external violation by limiting access to the computer sys-
tem by individual user name and password protection.
In order to minimize missing or wrong data, external
monitoring for the main outcome variables is planned,
including clinical and radiological variables for at least
10% of randomly selected participants.
Statistical methods
Sample size calculation representative for our population
concerning prevalence of silent infarcts has been esti-
mated using data of population-based studies published
before, which reported specific data on silent brain in-
farcts prevalence in participants aged 50 to 70 years old
[27-30]. According to them, the expected prevalence
should be about 10%. Therefore, after applying the Ene
2.0 software, with a confidence interval of 95% and an
accuracy of 2%, sample size should be of at least 865 in-
dividuals, which was increased to 1000 individuals by
taking into account possible losses.
Statistical analysis will be performed with the SPSS
15.0 statistical package (Chicago, Ill., USA). Statistical
significance for intergroup differences will be assessed
by the χ2 or Fisher’s exact test for categorical variables
and by the T-test, ANOVA, Mann–Whitney U and
Kruskal-Wallis test for continuous variables. The corre-
lations between continuous variables will be determined
with Spearman’s or Pearson’s coefficients, as appropriate.
A p value <0.05 will be considered significant. Logistic
regression models will be performed to identify potential
predictors of silent brain infarcts and other silent lesions.
Finally, Cox proportional hazards multivariate analysis
will be used to identify clinical predictors of stroke/TIA or
further CVE, adjusted by variables showing p values <0.1
on univariate testing. Results will be shown as OR
or HR, as appropriate, with their corresponding 95%
confidence intervals.
Discussion
Silent brain infarcts have been recently included into the
new definition of stroke, given that their high prevalence
and clinical consequences, such as further strokes and
cognitive decline do not support to treat them as inno-
cent findings anymore.
Although it is known that silent infarcts are associated
with age and vascular risk factors, particularly hyperten-
sion, there is limited information on the prevalence of
this condition in our setting. Studies restricted tohipertensives participants have been performed mainly
in Asian populations and they are mostly cross-sectional,
with no prospective follow-up to address either the
incidence of new lesions on imaging or the presence of
future strokes or cognitive decline.
ISSYS is designed to investigate both the prevalence of
silent brain infarcts and the incidence of strokes, cognitive
decline and appearance of new brain infarcts after three
years of follow-up in a cohort of 1000 Mediterranian
hypertensives.
Moreover, we will study the risk factors associated
with their presence and the relationship between them
and other hypertensive target organ damage, such as
those occurring in heart, kidney or vessels, in order to
know their single and combined contribution to the
global vascular risk in each patient.
Hopefully, the better knowledge on the frequency and
determinants of these lesions will help in the future to
optimize treatments or establish new preventive strat-
egies to minimize clinical and socioeconomic conse-
quences of stroke and dementia.
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